These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
150 related articles for article (PubMed ID: 6376558)
61. Effect of prolonged treatment with levamisole on vitiligo with limited and slow-spreading disease. Pasricha JS; Khera V Int J Dermatol; 1994 Aug; 33(8):584-7. PubMed ID: 7960359 [TBL] [Abstract][Full Text] [Related]
62. Comparative efficacy of halcinonide and fluocinonide creams in psoriasis and eszematous dermatoses. Sudilovsky A; Clewe TH J Clin Pharmacol; 1975; 15(11-12):779-84. PubMed ID: 1104668 [TBL] [Abstract][Full Text] [Related]
63. Harnessing autoimmunity (vitiligo) to treat melanoma: a myth or reality? Ram M; Shoenfeld Y Ann N Y Acad Sci; 2007 Sep; 1110():410-25. PubMed ID: 17911456 [TBL] [Abstract][Full Text] [Related]
64. Detection of antibodies to human melanoma cells in vitiligo and alopecia areata by Western blot analysis. Hann SK; Koo SW; Kim JB; Park YK J Dermatol; 1996 Feb; 23(2):100-3. PubMed ID: 8839236 [TBL] [Abstract][Full Text] [Related]
65. Treatment of psoriasis with amcinonide 0.1 percent and fluocinonide 0.05 percent ointments. A comparative double-blind study. Engel MF Cutis; 1982 Jun; 29(6):646-50. PubMed ID: 7049592 [TBL] [Abstract][Full Text] [Related]
66. Double-blind comparison of topical halcinonide and fluocinonide in the treatment of psoriasis. Close JE Int J Dermatol; 1976 Sep; 15(7):534-7. PubMed ID: 786910 [No Abstract] [Full Text] [Related]
68. Hypopigmentation, vitiligo, and melanoma. New data, more enigmas. Nordlund JJ Arch Dermatol; 1987 Aug; 123(8):1005-8. PubMed ID: 3631979 [No Abstract] [Full Text] [Related]
69. Immunoprecipitation of melanogenic enzyme autoantigens with vitiligo sera: evidence for cross-reactive autoantibodies to tyrosinase and tyrosinase-related protein-2 (TRP-2). Kemp EH; Gawkrodger DJ; Watson PF; Weetman AP Clin Exp Immunol; 1997 Sep; 109(3):495-500. PubMed ID: 9328128 [TBL] [Abstract][Full Text] [Related]
70. Multicenter study comparing 0.05% gel formulations of desoximetasone and fluocinonide in patients with scalp psoriasis. Willis I; Cornell RC; Penneys NS; Zaias N Clin Ther; 1986; 8(3):275-82. PubMed ID: 3521856 [TBL] [Abstract][Full Text] [Related]
71. [Lymphocyte transformation by melanin antigens in vitiligo vulgaris and malignant melanoma (author's transl)]. Yamada M; Fujimoto F; Higashi K; Yanase K; Oku T Nihon Hifuka Gakkai Zasshi; 1975 May; 85(6):351-8. PubMed ID: 1081153 [No Abstract] [Full Text] [Related]
72. Autoantibodies to tyrosinase: the bridge between melanoma and vitiligo. Fishman P; Merimski O; Baharav E; Shoenfeld Y Cancer; 1997 Apr; 79(8):1461-4. PubMed ID: 9118024 [TBL] [Abstract][Full Text] [Related]
76. The role of tyrosinase in autoimmune vitiligo. Song YH; Connor E; Li Y; Zorovich B; Balducci P; Maclaren N Lancet; 1994 Oct; 344(8929):1049-52. PubMed ID: 7934446 [TBL] [Abstract][Full Text] [Related]
77. Fluocinonide compared with betamethasone in the treatment of eczema and psoriasis. Ronn HH Practitioner; 1976 Jun; 216(1296):704-6. PubMed ID: 781661 [TBL] [Abstract][Full Text] [Related]
78. Malignant melanoma and vitiligo-like leukoderma: an electron microscopic study. Koh HK; Sober AJ; Nakagawa H; Albert DM; Mihm MC; Fitzpatrick TB J Am Acad Dermatol; 1983 Nov; 9(5):696-708. PubMed ID: 6643768 [TBL] [Abstract][Full Text] [Related]
79. Detection of antibodies to melanocytes in vitiligo by specific immunoprecipitation. Naughton GK; Eisinger M; Bystryn JC J Invest Dermatol; 1983 Dec; 81(6):540-2. PubMed ID: 6196421 [TBL] [Abstract][Full Text] [Related]
80. Melanoma-associated leukoderma and vitiligo cannot be differentiated based on blinded assessment by experts in the field. Lommerts JE; Teulings HE; Ezzedine K; van Geel N; Hartmann A; Speeckaert R; Spuls PI; Wolkerstorfer A; Luiten RM; Bekkenk MW J Am Acad Dermatol; 2016 Dec; 75(6):1198-1204. PubMed ID: 27717621 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]